Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Brewing has taken place since at least the 11th millennium BC, and archaeological evidence suggests that prehistoric peoples and later civilisations, including those in China, ancient Egypt, and Mesopotamia brewed beer. Descriptions of beer production can be found in cuneiform (the oldest known writing) from ancient Mesopotamia. In Mesopotamia the brewer's craft derived social sanction and divine protection from female deities/goddesses, specifically: Ninkasi, who covered the production of beer, Siris, who was used in a metonymic way to refer to beer, and Siduri, who appears in the Epic of Gilgamesh as a divine alewife or tavern-keeper, covered the enjoyment of beer. In pre-industrial times, and in developing countries, women are frequently the main brewers. As almost any cereal containing certain sugars can undergo spontaneous fermentation due to wild yeasts in the air and on the grains, it is possible that beer-like beverages were independently developed throughout the world in prehistoric times. The earliest archaeological evidence for cereal-based beer brewing has been found at Raqefet Cave in present-day Israel, where analysis of stone mortars indicates that the Natufians, a semi-sedentary foraging people, brewed wheat- or barley-based beer around 13,000 years ago, probably for ritual feasts. The brewing of beer at Raqefet Cave predates the appearance of domesticated cereals in the Near East by several millennia.
== Sources == Flegel, Melinda J. (2004). Sport first aid: A coach's guide to preventing and responding to injuries. Hong Kong, Japan: Human Kinetics. Lindsay, R., Watson, G., Hickmont, D., Broadfoot, A., & Bruynel, L. (1994). Treat your own strains sprains and bruises. New Zealand: Spinal Publications. Lovering, R.M. (2008). "Physical therapy and related interventions". In P.M. Tiidus (ed.), Skeletal muscle damage and repair (pp. 219–230). United States of America: Human Kinetics. Prentice, William E. "Tissue Response to Injury", Principles of Athletic Training: A Competency Based Approach. 14th ed. New York: McGraw Hill Companies, 2011. 260–277. Subotnick, Steven (1991). Sports and Exercise Injuries: Conventional, Homeopathic and Alternative Treatments. California, United States of America: North Atlantic Books.
The Washington Post also followed up with a correction of errors in its earlier report on the Smithsonian acquisition, stating that it incorrectly referred to Ayyadurai as the inventor of electronic messaging; the 'bcc', 'cc', 'to' and 'from' fields existed previously; Ayyadurai had not been honored as the "inventor of email". Writing for Gizmodo, Sam Biddle argued that email was developed a decade before EMAIL, beginning with Ray Tomlinson's sending the first text letter between two ARPANET-connected computers in 1971. Biddle quoted Tomlinson: "[We] had most of the headers needed to deliver the message (to:, cc:, etc.) as well as identifying the sender (from:) and when the message was sent (date:) and what the message was about." Biddle allowed for the possibility that Ayyadurai may have coined the term "EMAIL" and used the header terms without being aware of earlier work, but maintained that the historical record isn't definitive on either point. Biddle wrote that "laying claim to the name of a product that's the generic term for a universal technology gives you acres of weasel room.
Sources: en.wikipedia.org
The SPD's Hamburg Programme (2007) describes democratic socialism as "an order of economy, state and society in which the civil, political, social and economic fundamental rights are guaranteed for all people, all people live a life without exploitation, oppression and violence, that is in social and human security" and as a "vision of a free, just and solidary society", the realisation of which is emphasised as a "permanent task." Social democracy serves as the "principle of action." On 25 May 2014, the Spanish left-wing party Podemos entered candidates for the 2014 European parliamentary election, some of which were unemployed. In a surprise result, it won 7.98% of the vote and was awarded five seats out of 54 while the older United Left was the third largest overall force, obtaining 10.03% and five seats, four more than the previous elections. Although losing seats in both the April 2019 and November 2019 general elections, the result of the latter being a failure of negotiations with the Spanish Socialist Workers' Party (PSOE), Podemos reached an agreement with the PSOE for a full four-year coalition government, the first such government since the country's transition to democracy in 1976. While failing to get the necessary 176 out of 350 majority investiture vote on 5 January 2020, the PSOE–Unidas Podemos coalition government was able to get a simple majority (167–165) on 7 January 2020 and the new cabinet was sworn into office the following day.
Medical education and training varies around the world. It typically involves entry level education at a university medical school, followed by a period of supervised practice or internship, or residency. This can be followed by postgraduate vocational training. A variety of teaching methods have been employed in medical education, still itself a focus of active research. In Canada and the United States of America, a Doctor of Medicine degree, often abbreviated M.D., or a Doctor of Osteopathic Medicine degree, often abbreviated as D.O. and unique to the United States, must be completed in and delivered from a recognized university. Since knowledge, techniques, and medical technology continue to evolve at a rapid rate, many regulatory authorities require continuing medical education. Medical practitioners upgrade their knowledge in various ways, including medical journals, seminars, conferences, and online programs. A database of objectives covering medical knowledge, as suggested by national societies across the United States, can be searched at http://data.medobjectives.marian.edu/ Archived 4 October 2018 at the Wayback Machine.
The NHS questioned the benefits of the medication for depression and claimed that it was too expensive. People already using esketamine were allowed to complete treatment if their doctors considered this necessary. Esketamine is approved in the United States for and shows promise as a rapid-acting monotherapy for treatment-resistant depression, but evidence is currently limited to a single trial. It is an effective and generally safe long-term treatment for adults with treatment-resistant depression, feasible in outpatient settings; optimal oral antidepressant combinations and predictive biomarkers need further research. Spravato debuted at a cost of treatment of US$32,400 per year when it launched in the United States in March 2019. The Institute for Clinical and Economic Review (ICER), which evaluates cost effectiveness of drugs analogously to the National Institute for Health and Care Excellence (NICE) in the United Kingdom, declined to recommend esketamine for depression due to its steep cost and modest efficacy, deeming it not sufficiently cost-effective. Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people with a partial response to treatment.
== Sources == This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food and Agriculture 2019. Moving forward on food loss and waste reduction, In brief, 24, FAO, FAO.
Sources: en.wikipedia.org
=== Lung === Chronic obstructive pulmonary disease (COPD) is one of the most widespread health threats today. It affects 329 million people worldwide, which makes up nearly 5% of the global population. Having killed over 3 million people in 2012, COPD was the third greatest cause of death. Worse still, due to increasing smoking rates and the aging populations in many countries, the number of deaths as a result of COPD and other chronic lung diseases is predicted to continue increasing. Therefore, developments in the lung's capacity for regeneration is in high demand. It has been shown that bone marrow-derived cells could be the source of progenitor cells of multiple cell lineages, and a 2004 study suggested that one of these cell types was involved in lung regeneration. Therefore, a potential source of cells for lung regeneration has been found; however, due to advances in inducing stem cells and directing their differentiation, major progress in lung regeneration has consistently featured the use of patient-derived iPSCs and bioscaffolds. The extracellular matrix is the key to generating entire organs in vitro. It was found that by carefully removing the cells of an entire lung, a "footprint" is left behind that can guide cellular adhesion and differentiation if a population of lung epithelial cells and chondrocytes are added. This has serious applications in regenerative medicine, particularly as a 2012 study successfully purified a population of lung progenitor cells that were derived from embryonic stem cells.
The enzyme is a cytochrome P450 protein containing heme, isolated from peppermint. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
=== Political changes === The revolution brought Romania vast attention from the outside world. Initially, much of the world's sympathy went to the FSN government under Ion Iliescu, a former member of the CPR leadership and a Ceaușescu ally prior to falling into the dictator's disfavour in the early 1980s. The FSN, composed mainly of former members of the second echelon of the CPR, immediately assumed control over the state institutions, including the main media outlets such as the national radio and television networks. They used their control of the media to launch attacks against their political opponents, newly created political parties that claimed to be successors to those existing before 1948. Around the same time, all Romanian numbers stations ceased transmitting, including a number station called "Ciocârlia/The Skylark", also known as "V01" after the revolution. Much of that sympathy was squandered during the Mineriads. Massive protests erupted in downtown Bucharest as political rallies organised by the opposition parties during the presidential elections, with a small part of the protesters deciding to stand ground even after Iliescu was re-elected with an overwhelming majority of 85%. Attempts by police to evacuate the remaining protesters resulted in attacks on state institutions, prompting Iliescu to appeal to the country's workers for help. Infiltrated and instigated by former Securitate agents, in the following days a large mass of workers, mainly miners, entered Bucharest and attacked and fought with anti-government protesters and gathered bystanders.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.